Company commences Technegas trial in U.S.

11/20/2012 | ProactiveInvestors.co.au (Australia)

Cyclopharm has enrolled the first patient in a U.S. clinical trial involving its Technegas product, a gas inhaled by patients before imaging to improve detection of blood clots in the lungs. The multi-center study will eventually involve 750 patients and is expected to be completed in 18 months.

View Full Article in:

ProactiveInvestors.co.au (Australia)

Published in Brief:

SmartBrief Job Listings for Health Care